Molecular Weight | 373.4 g/mol |
---|---|
Molecular Formula | C21H15N3O4 |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 2 |
Exact Mass | 373.10625597 g/mol |
Monoisotopic Mass | 373.10625597 g/mol |
Topological Polar Surface Area | 98.7 A^2 |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 912 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Exjade |
PubMed Health | Deferasirox (By mouth) |
Drug Classes | Heavy Metal Chelator |
Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
Active Ingredient | Deferasirox |
Dosage Form | Tablet, for suspension |
Route | Oral |
Strength | 250mg; 125mg; 500mg |
Market Status | Prescription |
Company | Novartis |
2 of 2 | |
---|---|
Drug Name | Exjade |
PubMed Health | Deferasirox (By mouth) |
Drug Classes | Heavy Metal Chelator |
Drug Label | Exjade(deferasirox) is an iron chelating agent. Exjade tablets for oral suspension contain 125mg, 250mg, or 500mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its st... |
Active Ingredient | Deferasirox |
Dosage Form | Tablet, for suspension |
Route | Oral |
Strength | 250mg; 125mg; 500mg |
Market Status | Prescription |
Company | Novartis |
LOOKING FOR A SUPPLIER?